This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Today's Health Winners and Losers

Charles River Laboratories (CRL - Get Report) shares moved higher after the company posted better-than-expected fourth-quarter earnings and in-line guidance for 2006. The company, which provides services for pharmaceutical companies, earned $50.4 million, or 69 cents a share, compared with $20.1 million, or 32 cents a share, a year earlier. Excluding items, earnings were 59 cents a share, topping Wall Street's projection by 2 cents. Revenue rose 22% to $291.2 million, surpassing analysts' target of $282.8 million.

Charles River expects 2006 earnings of $2.46 to $2.52 a share, excluding stock options expenses and one-time items. The forecast brackets analysts' mean estimate of $2.48 a share. The company's shares recently changed hands at $48.22, up $3.37, or 7.5%.

Conmed (CNMD - Get Report) dropped 12% after the medical equipment supplier posted fourth-quarter results that missed forecasts and warned that first-quarter results also would be weaker than expected. The company earned $2.8 million, or 10 cents a share, on sales of $153.2 million. Excluding items, Conmed earned $5.3 million, or 18 cents a share. Analysts expected earnings of 27 cents a share and sales of $160.5 million. Results were hurt by lower-than-expected surgical procedures, foreign currency translation, and extended capital equipment purchasing decision timelines in certain markets, the company said. During the year-earlier quarter, Conmed posted adjusted earnings of $14.7 million, or 49 cents a share, on sales of $161.2 million.

For the first quarter, Conmed projects earnings of 18 cents to 22 cents a share, below analysts' prediction of 38 cents. The company forecast sales of $153 million to $158 million, compared with Wall Street's target of $162.5 million. Shares were down $2.87 to $20.79.

Shares of Chattem (CHTT) tumbled 12% after the seller of health products posted fourth-quarter earnings that were a penny short of forecasts. The company earned $2.4 million, or 12 cents a share. Excluding items, the company earned $8.6 million, or 43 cents a share. Analysts expected earnings of 44 cents a share. Sales totaled $63.9 million, just shy of analysts' projection of $63.7 million. During the year-earlier period, the company posted adjusted earnings of $7.2 million, or 35 cents a share, on sales of $60.7 million.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BMY $63.56 0.00%
CNMD $51.18 0.00%
CRL $78.69 0.00%
AAPL $124.25 0.00%
FB $81.66 0.00%

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs